Anavex Life Sciences Corp (AVXL)

[XenaLives]

This is the problem with Lipitor..

What Are Side Effects of Lipitor?
Side effects of Lipitor include:

constipation,
diarrhea,
nausea,
fatigue,
gas,
heartburn,
headache, and
mild muscle pain.
Contact your doctor if you experience serious side effects of Lipitor including:

muscle wasting and muscle breakdown (rhabdomyolysis),
confusion or memory problems,
fever,
dark urine,
increased thirst or hunger,
drowsiness,
loss of appetite, or
yellowing of the skin or eyes (jaundice).

https://www.rxlist.com/lipitor-side-effects-drug-center.htm

Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism
Beatrice A Golomb 1, Marcella A Evans
Affiliations expand
PMID: 19159124 PMCID: PMC2849981 DOI: 10.2165/0129784-200808060-00004
Free PMC article
Abstract
HMG-CoA reductase inhibitors (statins) are a widely used class of drug, and like all medications, have potential for adverse effects (AEs). Here we review the statin AE literature, first focusing on muscle AEs as the most reported problem both in the literature and by patients. Evidence regarding the statin muscle AE mechanism, dose effect, drug interactions, and genetic predisposition is examined. We hypothesize, and provide evidence, that the demonstrated mitochondrial mechanisms for muscle AEs have implications to other nonmuscle AEs in patients treated with statins. In meta-analyses of randomized controlled trials (RCTs), muscle AEs are more frequent with statins than with placebo. A number of manifestations of muscle AEs have been reported, with rhabdomyolysis the most feared. AEs are dose dependent, and risk is amplified by drug interactions that functionally increase statin potency, often through inhibition of the cytochrome P450 3A4 system. An array of additional risk factors for statin AEs are those that amplify (or reflect) mitochondrial or metabolic vulnerability, such as metabolic syndrome factors, thyroid disease, and genetic mutations linked to mitochondrial dysfunction. Converging evidence supports a mitochondrial foundation for muscle AEs associated with statins, and both theoretical and empirical considerations suggest that mitochondrial dysfunction may also underlie many nonmuscle statin AEs. Evidence from RCTs and studies of other designs indicates existence of additional statin-associated AEs, such as cognitive loss, neuropathy, pancreatic and hepatic dysfunction, and sexual dysfunction. Physician awareness of statin AEs is reportedly low even for the AEs most widely reported by patients. Awareness and vigilance for AEs should be maintained to enable informed treatment decisions, treatment modification if appropriate, improved quality of patient care, and reduced patient morbidity.

https://pubmed.ncbi.nlm.nih.gov/19159124/